www.standoutstocks.com: Stocks That Stand Out For Nov. 13th, 2009 Are HRRN, SCLN, HEPH, CYTK

Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354 Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at HYPERLINK "http://www.Standoutstocks.com/" www.Standoutstocks.com

_________________________________________________

He-5 Resources Corp. Announces Launching of TBBN.TV ("Trading Barter Bank Network") Beta Module Scheduled for Today 5:00pm Eastern Time

NEW YORK CITY, NEW YORK, Nov 13, 2009 -- HE-5 Resources, Corp. (PINK SHEETS: HRRN), announced today the launch of TBBN.TV (Trading Barter Bank Network) Beta module scheduled for 5:00pm Eastern Time.

Mr. Rick DesOrmeaux, newly appointed President and COO of the Company, has initiated the Public "Trading Barter Bank" Beta Module Release Program. This initiative is the first of many corporate measures he has planned to accelerate TBB Market venue and begin building revenues rapidly.

Mr. DesOrmeaux stated: "Our Shareholders need to understand the business model and see our dynamic and interactive approach. For many months now, I've been attending Friday afternoon Beta testing meetings. After every presentation, I was motivated and interested to learn more about all the unique features of this project. I now feel it's time for everyone to participate and even help out by posting objective and constructive opinions and comments." Rick added: "I want our "United Business Traders" to be part of the operation and stimulate the Member philosophy and Fellowship through and by interacting in the process. We will continue to launch our module every week like before my nomination, but now, every single beta test will be semi-public. We will create a section in our forum dedicated specifically for Members' and Traders' input and we will publish after each beta test a more detailed explanation of the module functionalities in order to help our shareholders to understand the unique values and exclusive features of the "Trading Barter Bank" platform.

Management greatly appreciates "United Business Traders" support.

Management will keep the shareholders informed and we invite you to visit our forum at www.unitedbusinesstraders.com and suggest that you complete the online registration form in order to receive member packages.

You may also visit our corporate website at: www.tradingbartercorp.com; And our Blog at: www.tradingbarterblog.com.

Forward-Looking Statements Please be advised that statements made herein, other than historical, constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, potential volatility in the company's stock price, increased competition, customer acceptance of new products and services offered by the company, and uncertainty of future revenue and profitability and fluctuations in its quarterly operating results. Please also be advised that the company's stock is not currently registered with the Securities and Exchange Commission.

SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings

Compound's Anti-Cancer Properties Highlighted at Annual AACR-NCI-EORTC Meeting as Well as Cold Spring Harbor Laboratory's Winter Biotech Conference

FOSTER CITY, CA, Nov 12, 2009 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN | Quote | Chart | News | PowerRating) today announced presentations of multiple abstracts demonstrating SCV-07's anti-tumor immunomodulating properties at two upcoming events: Cold Spring Harbor Laboratory's Harnessing Immunity to Prevent and Treat Disease meeting; and the American Association for Cancer Research (AACR), National Cancer Institute (NCI), and European Organization for Research and Treatment of Cancer (EORTC)'s Molecular Targets and Cancer Therapeutics International Conference. The presentations include data on SCV-07's role as a breast cancer adjuvant, its efficacy in treating B16 melanoma, and its effect on STAT3-related immune responses.

SCV-07 (gamma-D-glutamyl-L-tryptophan) is a small molecule which stimulates the immune system through inhibition of STAT3 signaling and the resulting effects on T-helper 1 cells. SCV-07 has been shown to be efficacious in animal models of immune-sensitive diseases, including viral infections and cancers, and in the enhancement of response to vaccines. The compound has demonstrated an ability, for example, to reduce progression of renal and lung carcinoma as well as melanoma in mouse models.

Additionally, SciClone is conducting a phase 2 multicenter, randomized, double-blind, placebo-controlled, dose ranging study, designed to assess the safety and efficacy of SCV-07 for the delay to onset and severity of severe oral mucositis in patients receiving standard chemoradiation therapy for treatment of cancers of the head and neck. SciClone expects to complete enrollment in this study in the second half of 2009 and provide initial results in the first half of 2010.

SciClone is also currently running a multicenter, multidose, open label phase 2 clinical trial of SCV-07 as a monotherapy and in combination with ribavirin to treat hepatitis C virus. SCV-07 has shown a good safety profile in several early stage clinical trials in healthy volunteers and subjects with HCV infection at various doses. SciClone expects to complete enrollment in this study in the first half of 2010 and provide initial results in the second half of 2010.

The Novel Immunomodulator SCV-07 Provides Enhancement to a Breast Cancer Vaccine In a study conducted by colleagues at the University of Washington in Seattle, Cynthia Tuthill, Ph.D., SciClone's Senior Vice President of Scientific Affairs and Chief Scientific Officer, obtained data on SCV-07's role as a breast cancer vaccine adjuvant in a mouse model of HER-2 positive breast cancer. It was shown that SCV-07 helped stimulate a shift of T helper cells to the Th1 profile of cytokines and was able to enhance the host's response to a breast cancer vaccine as determined by an inhibition of tumor growth. These findings will be shared during an oral presentation at the Cold Spring Harbor Laboratory's Harnessing Immunity to Prevent and Treat Disease meeting on November 12, 2009 at 2 pm ET in Cold Spring Harbor, NY.

Extended Survival of Mice Bearing B16 Melanoma after Treatment with SCV-07 During a poster session at the Cold Spring Harbor meeting, Dr. Tuthill will present data on SCV-07's efficacy -- both alone and in combination with chemotherapy -- in treating mice with B16 melanoma. Combination treatment with chemotherapy and SCV-07 in a melanoma mouse model demonstrated beneficial effects as reflected by increased survival and decreased treatment toxicity. The poster will be presented at the Harnessing Immunity to Prevent and Treat Disease meeting, during the evening session on November 12, 2009 in Cold Spring Harbor, NY.

The Anti-tumor Activity of SCV-07 Is Attributable in Part to an Inhibitory Effect on STAT3 Driven Responses Additional data on SCV-07 will be presented in a poster session at the annual AACR-NCI-EORTC meeting at which Dr. Tuthill and colleagues will discuss SCV-07's effect on STAT3. Because STAT3 is known to be up-regulated in tumor microenvironments, and STAT3-driven gene expression triggers global immune suppression of anti-tumor responses, SCV-07 was tested to determine whether or not it modulates STAT3-induced responses as part of its mechanism in stimulating anti-tumor immune response. The results provide support that SCV-07 does in fact reduce STAT3-driven gene expression and leads to anti-tumor natural killer cell responses in the host. This poster (C107) will be presented at AACR-NCI-EORTC's Molecular Targets and Cancer Therapeutics International Conference on November 18, 2009 at 12:30 pm ET in Boston, MA.

SCV-07 is protected by composition of matter patents as well as multiple method of treatment patents. SciClone has exclusive worldwide rights to SCV-07 outside of Russia, where the molecule has recently been approved for stimulation of depressed immune systems.

About SciClone SciClone Pharmaceuticals (NASDAQ: SCLN | Quote | Chart | News | PowerRating) is a profitable, global specialty pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and overall expense management. ZADAXIN (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin, in preclinical studies as an enhancer of H1N1 flu vaccines; thymalfasin for stage IV melanoma, for which SciClone has reached agreement with the FDA on the design of a phase 3 trial; SCV-07 in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; and SCV-07 in a phase 2 trial for the treatment of HCV. SciClone has exclusive commercialization and distribution rights to DC Bead(TM) in China, where the product is under regulatory review. The Company also has exclusive commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm(TM) in China and Vietnam, for which it will seek regulatory approval. For additional information, please visit www.sciclone.com.

Forward-Looking Statements This press release contains forward-looking statements regarding development objectives and timing expectations. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "potential," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These risks and uncertainties include our ability to identify and consummate our previously-announced goals of acquiring additional products to sell, either through licensing or the acquisition of businesses. Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.

Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference

--- Company Provides Update on Progress of Lead Compounds -

SAN DIEGO, Nov 12, 2009 -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), will present results of its ongoing human clinical Phase I/II open-label dose-ranging trial with Apoptone(R) (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC) on November 16 at the American Association for Cancer Research - Molecular Targets and Cancer Therapeutics Conference in Boston. Apoptone, a novel steroid that is an analog of part of the dihydrotestosterone metabolic pathway, stimulates ERK1 signal transduction that counter-regulates PI3K, and thereby initiating tumor cell apoptosis. Apoptone has demonstrated activity in animal models of CRPC, the results of which were recently published in the British Journal of Cancer and the journal Neoplasia.

Concurrently with its lead program Apoptone, Hollis-Eden Pharmaceuticals is pursuing clinical development of a second oral small-molecule candidate, Triolex(R), from its synthetic steroid library. Triolex decreases macrophage infiltration into fatty tissues and pro-inflammatory processes. The lead indication for Triolex is Type 2 diabetes. A Phase II trial (HE3286-0401) in obese, insulin-resistant diabetic patients is fully enrolled and should be completed in the first quarter of 2010. A Phase I trial (HE3286-0102) to assess safety and early activity in obese insulin-resistant, pre-diabetic subjects is complete, with final analysis in progress. Additional trials were initiated during 2008 in rheumatoid arthritis (RA) and ulcerative colitis (UC).

James Frincke, Ph.D., Chief Executive Officer of Hollis-Eden Pharmaceuticals commented: "We have reduced our burn rate to enable operations focused on our lead programs to continue into the latter half of 2010. We intend to use data from our ongoing trials to engage with potential corporate partners for the design and funding of late-stage development programs in diseases with high unmet medical need." Triolex Clinical Program Update Diabetes Pre-diabetes Phase I safety tolerance and early activity trial HE3286-0102 This study has completed the planned enrollment of 48 patients and data analysis has been initiated. Preliminary results indicated that Triolex was safe and well-tolerated, and there were no side effects observed such as those seen with testosterone, estrogen, progesterone or glucocorticoids.

Diabetes Phase II two-stage exploratory and confirmatory trial HE3286-0401 This ongoing study in type 2 diabetic patients was undertaken based on promising Triolex activity in insulin-resistant, prediabetic subjects. The original study began in the second half of 2008. The initial exploratory phase included 84 days of treatment with Triolex or placebo along with metformin in patients with uncontrolled HbA1c levels. Activity was found in a subset of diabetics defined with biomarkers as obese, inflamed and insulin-resistant. A confirmatory, placebo-controlled trial was initiated in the second quarter of 2009 in patients dosed only with Triolex or placebo in order to avoid potential confounding effects of metformin on anti-inflammatory activity. The confirmatory stage of the trial is fully enrolled; the last patient is expected to complete the trial in the first quarter of 2010.

Other Inflammatory Diseases Two exploratory Phase I/II studies were initiated with Triolex in other diseases with an auto-immune inflammatory etiology. The results of these studies, combined with our completed non-clinical long-term toxicology data, will permit proof-of-concept trials in these indications as resources become available.

Ulcerative colitis Phase I/II safety, tolerance and early activity trial HE3286-0301 This Phase I/II trial explored the safety, tolerability and early signs of activity in chronic UC patients who were experiencing an acute flare in their disease. Patients were dosed for 28 days at 3 dose levels: 5 mg, 10 mg (5 bid) and 20 mg (10 bid) and Triolex was found to be safe and tolerable. Adverse events were mild to moderate and equally divided between Triolex and placebo-treated groups. The study was not powered to show statistically significant activity differences between placebo and drug-treated patients based on disease score changes. There was no clear separation between the placebo and active study arms over a one-month treatment period.

Rheumatoid arthritis Phase I safety, tolerance and drug compatibility study HE3286-0201 This Phase I safety and tolerance study was conducted in RA patients with stable disease that were concurrently taking methotrexate as maintenance therapy. A secondary objective of the study was to learn whether Triolex interfered with the action of methotrexate, which is required for concomitant dosing trials in patients with active disease. Three dose levels of Triolex were given daily to 14 subjects for 28 days along with weekly methotrexate. Three patients were dosed at 10 mg (5 mg bid), three at 20 mg (10 mg bid) and eight at 40 mg (2 mg bid) on an intent-to-treat basis.

Triolex was found to be safe and well tolerated. No disease flares or increased methotrexate toxicity were observed. Most adverse events were mild to moderate. Subject drug exposure remained dose proportional through the higher dose, and no change in methotrexate or Triolex pharmacokinetics was observed.

About Hollis-Eden Pharmaceuticals Hollis-Eden Pharmaceuticals is a development-stage company with two product candidates in human clinical trials: Apoptone (HE3235), in the dose-escalation portion of a Phase I/II trial of patients with late-stage prostate cancer, and Triolex, in a Phase IIa trial in obese Type 2 diabetes patients. Apoptone and Triolex represent the lead candidates from Hollis-Eden's small molecule platform based on metabolites or synthetic analogs of endogenous steroid hormones. For more information on Hollis-Eden please visit www.holliseden.com.

This press release contains forward-looking statements within the meaning of the federal securities laws concerning, among other things, the presentation of the results of Hollis-Eden Pharmaceuticals, Inc. ongoing human clinical Phase I/II open-label dose-ranging trial with Apoptone (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC) on November 16; the completion of Hollis-Eden's Phase II trial (HE3286-0401) in obese, insulin-resistant diabetic patients in the first quarter of 2010; the continuation of Hollis-Eden's operations focused on its lead programs into the latter half of 2010; Hollis-Eden's use of data from its ongoing trials to engage with potential corporate partners for the design and funding of late-stage development programs; and Hollis-Eden's ability to conduct proof-of-concept trials in other diseases with an auto-immune inflammatory etiology as resources become available. Any statement included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause Hollis-Eden's actual results to differ materially from historical results or those expressed or implied by such forward-looking statements. Such statements are subject to certain risks and uncertainties inherent in the Company's business, including, but not limited to: the ability to complete preclinical and clinical trials successfully and within specified timelines, if at all; the ability to obtain regulatory approval for TRIOLEX (HE3286), APOPTONE (HE3235) or any other investigational drug candidate; the Company's future capital needs; the Company's ability to obtain additional funding; the ability of the Company to protect its intellectual property rights and to not infringe the intellectual property rights of others; the development of competitive products by other companies; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, Hollis-Eden undertakes no obligation to update or revise the information contained in this press release as a result of new information, future events or circumstances arising after the date of this press release.

Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to Be Presented at the 2009 AACR-NCI-EORTC International Conference

SOUTH SAN FRANCISCO, CA, Nov 12, 2009 -- Cytokinetics, Incorporated (NASDAQ: CYTK | Quote | Chart | News | PowerRating) announced today that abstracts summarizing non-clinical data relating to GSK-923295, an inhibitor of centromere-associated protein E (CENP-E), are scheduled to be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held from November 15-19, 2009 at the Hynes Convention Center in Boston, Massachusetts.

The presentations contain preclinical data relating to GSK-923295, currently being studied in a GlaxoSmithKline sponsored Phase I, first time in humans clinical trial designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of this novel drug candidate in patients with solid tumors.

Poster Presentations at AACR-NCI-EORTC Symposium: Poster #B173: "Synergistic Interaction Between CENP-E inhibitor GSK923295 and MEKi Inhibitor GSK1120212," is scheduled to be displayed on Tuesday, November 17 from 12:30 PM - 2:30 PM Eastern Time in Halls C-D at the Poster Session B: New Molecular Targets 1. The poster will be presented by the author, Yan Y. Degenhardt, Ph.D., Manager, Cancer Metabolism, Oncology R&D,GlaxoSmithKline.

Poster #PR-10 "RNAi-directed Identification of Chemosensitizers of GSK923295 Response," is scheduled to be displayed on Wednesday, November 18 from 12:30 PM - 2:30 PM Eastern Time in Poster Session C: Pharmacogenetics, Pharmacogenomics, and Therapeutic Response in Halls C-D. The poster will be presented by the author, Holly Yin, Ph.D., Head of Cellular Genomics, Translational Genomics Research Institute (TGen).

Oral Presentation at AACR-NCI-EORTC Symposium: "RNAi-directed Identification of Chemosensitizers of GSK923295 Response," is scheduled to be presented as part of the Proffered Paper Session on Wednesday, November 18 from 4:30 - 5:30 PM Eastern Time. The presentation will be made by Holly Yin, Ph.D., Head of Cellular Genomics, Translational Genomics Research Institute (TGen).

About Cytokinetics Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil (formerly CK-1827452), is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is in Phase I clinical development. Cytokinetics is also conducting non-clinical development of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions such as systemic hypertension, pulmonary arterial hypertension or bronchoconstriction. In addition, prior Cytokinetics' research generated three anti-cancer drug candidates in Phase I clinical development: ispinesib, SB-743921 and GSK-923295. Cytokinetics is seeking a partner for ispinesib and SB-743921 and GSK-923295 is being developed under Cytokinetics' collaboration with GlaxoSmithKline. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

About Standoutstocks.com www.Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

www.Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at http://www.Standoutstocks.com and select the "join now" button.

Join us at http://www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: http://www.standoutstocks.com/disclaimer.aspx

CONTACT: Jason A. Hilton, Standout Stocks
Tel: +1 585 729 8809
e-mail: Jason@Newmediaadvisorsllc.com
e-mail: info@standoutstocks.com
WWW: http://www.standoutstocks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on Sciclone Pharmaceutical (SCLN) SCLN. Sciclone Pharmaceutical (SCLN) has Short Term PowerRatings at TradingMarkets. Details on Sciclone Pharmaceutical (SCLN) Short Term PowerRatings is available at This Link.

For full details on (HRRN) HRRN. (HRRN) has Short Term PowerRatings at TradingMarkets. Details on (HRRN) Short Term PowerRatings is available at This Link.

For full details on Cytokinetics (CYTK) CYTK. Cytokinetics (CYTK) has Short Term PowerRatings at TradingMarkets. Details on Cytokinetics (CYTK) Short Term PowerRatings is available at This Link.

For full details on Hollis-eden Pharmaceut (HEPH) HEPH. Hollis-eden Pharmaceut (HEPH) has Short Term PowerRatings at TradingMarkets. Details on Hollis-eden Pharmaceut (HEPH) Short Term PowerRatings is available at This Link.